Thu.Jul 11, 2024

article thumbnail

Senate unanimously endorses legislation targeting pharma 'patent thickets'

Fierce Pharma

Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to cr | The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition.

Pharma 351
article thumbnail

Closing the Gap in Medications for the Treatment of Alcohol Use Disorder (AUD)

MedCity News

By understanding that AUD is a diagnosable and treatable medical condition with individualized impact, we can tailor treatments to meet patients’ specific needs. Effective treatment for AUD is multifaceted, involving medical, psychological, and social support. The post Closing the Gap in Medications for the Treatment of Alcohol Use Disorder (AUD) appeared first on MedCity News.

Medical 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The end of the beginning: Lilly execs eye top spot in burgeoning Alzheimer's market after Kisunla's FDA approval

Fierce Pharma

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | On top of Eisai and Biogen's Leqembi, Kisunla’s approval likely marks the “end of the beginning in treating this disease,” Andrew Lechleiter, VP of U.S.

Marketing 317
article thumbnail

Will A Divestiture Save the UnitedHealth Group-Amedisys Deal?

MedCity News

Amedisys and UnitedHealth Group plan to divest care centers to an affiliate of VitalCaring Group. Several experts said this will likely clear the way for the companies’ merger. The post Will A Divestiture Save the UnitedHealth Group-Amedisys Deal? appeared first on MedCity News.

124
124
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Citing manufacturing issue, FDA rejects Novo Nordisk's once-weekly insulin

Fierce Pharma

In surging to the top spot in the market cap rankings in Europe, Novo Nordisk has been on an extended winning streak. | The FDA has slowed the roll for Novo Nordisk, rejecting its once-a-week insulin icodec for patients with Type 1 and Type 2 diabetes. In a complete response letter, the U.S. regulator made "requests related to the manufacturing process and the type 1 diabetes indication," which the company said it does not expect to remedy by the end of this year.

article thumbnail

FTC said to be planning legal action against PBMs

pharmaphorum

The FTC is said to be gearing up to file lawsuits against the top three pharmacy benefit managers in the wake of its damning report on the sector.

More Trending

article thumbnail

Bill that would cut down ‘patent thickets’ clears Senate

pharmaphorum

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the prices of medicines in the US.

article thumbnail

After $185M asset buy, Merz Therapeutics plots US workforce expansion as CEO eyes more deals

Fierce Pharma

Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear. | Equipped with two approved meds from Acorda Therapeutics, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.

278
278
article thumbnail

Clarivate launches Academia AI Advisory Council

Clarivate

“AI Everywhere All at Once.” This year’s theme from Outsell, Inc. perfectly captures the expansion of artificial intelligence across all facets of our lives. In academia, this rapid advancement raises more questions than answers. How do we ensure ethical AI use? How can we advance research and drive research integrity? How do we use AI to advance student learning skills?

Ethics 122
article thumbnail

AbbVie asks Supreme Court to uphold attorney-client privilege in AndroGel lawsuit

Fierce Pharma

AbbVie is asking the U.S. | AbbVie is asking the U.S. Supreme Court to overrule a lower court's ruling that the company must turn over records of communications with its lawyers regarding a patent lawsuit it filed against a generic drug maker more than a decade ago.

277
277
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Clinical trial trends and the rise of site networks

pharmaphorum

Tune in to Caroline Redecker and Jason Casarella as they discuss clinical trial trends and the rise of site networks in this insightful podcast episode brought to you by Advanced Clinical.

article thumbnail

Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season

Fierce Pharma

The dog days of summer might be in full swing, but for flu vaccine makers, its a busy time prepping for this fall's influenza season. | The companies started distributing shipments of their respective vaccine options ahead of the fall flu season as the CDC recommends vaccination before the virus spreads.

article thumbnail

FDA rejects Novo Nordisk’s weekly basal insulin

pharmaphorum

FDA rejects Novo Nordisk’s once-weekly basal insulin for people with diabetes, which would reduce the number of injections needed

FDA 111
article thumbnail

Find out what to expect from the PDA/FDA Joint Regulatory Conference

Fierce Pharma

In this episode of "The Top Line", sponsored by the Parenteral Drug Association (PDA), we do a deep dive into the highly anticipated PDA/FDA Joint Regulatory Conference, set to take place from Sept | We sat down with industry expert Janeen Skutnik-Wilkinson, the PDA/FDA Joint Regulatory Conference 2024 Co-Chair to give us an exclusive behind-the-scenes look at this must-attend CGMP event, set to take place from September 9-11 in Washington D.C.

FDA 130
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

New policy review reveals ten cancer challenges facing new UK government

PharmaTimes

Macmillan Cancer Support estimates that cancer affects over three million people in the UK

article thumbnail

AbbVie lines up Thakkar to replace outgoing CSO Hudson

pharmaphorum

Change of R&D chiefs at AbbVie, as Thomas Hudson steps down as CSO and is replaced by Roopal Thakkar.

109
109
article thumbnail

Ipsen Turns to China-Based Biotech to Get Another ADC Cancer Drug

MedCity News

Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen’s second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama. The post Ipsen Turns to China-Based Biotech to Get Another ADC Cancer Drug appeared first on MedCity News.

Biopharma 107
article thumbnail

AbbVie appoints new Chief Scientific Officer

European Pharmaceutical Review

Dr Roopal Thakkar has been appointed as Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie. He is the company ’s current Senior Vice President, Chief Medical Officer, Global Therapeutics. “As AbbVie’s Chief Scientific Officer, Dr Thakkar will continue to build momentum across discovery and all stages of development to fully realise the potential of our diverse pipeline.

Medicine 105
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Pharma Pulse 7/11/24: Thermo Fisher Scientific Completes Acquisition of Olink, 7 Takeaways From the FTC Interim Report on PBMs & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

Ipsen forges another ADC alliance, this time with Foreseen

pharmaphorum

Ipsen places another bet on an antibody-drug conjugate for cancer, pledging up to $1bn for a preclinical candidate from Foreseen Bio

104
104
article thumbnail

Researchers awarded £1.5m for national dementia inequalities network

PharmaTimes

The ESRC EquaDem Network Plus aims to improve disparities in diagnosis and care

article thumbnail

The Opportunity for Digital Innovation in Oncology Drug Development

MedCity News

Solving three major challenges in the development of new oncology drugs The post The Opportunity for Digital Innovation in Oncology Drug Development appeared first on MedCity News.

FDA 89
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FTC Intends to Sue Biggest Pharmacy Benefit Managers for Unfair Negotiating Tactics

Pharmacy Times

In a follow-up to the interim FTC report documenting the business practices of PBMs and the power they hold in the pharmaceutical industry, the Commission now seeks to sue the 3 largest PBMs in the country for driving up the price of insulin and other essential drugs.

article thumbnail

Hospital M&A Activity Remained Strong In Q2, Kaufman Hall Says

MedCity News

The number of hospital M&A deals may have fallen from Q1 to Q2 of this year, but that doesn’t mean that the hospital M&A space is lacking vitality, according to a new Kaufman Hall report. Rather, it means that the hospital M&A is shifting its emphasis from scale to strategy. The post Hospital M&A Activity Remained Strong In Q2, Kaufman Hall Says appeared first on MedCity News.

69
article thumbnail

PharmassêtX gains FDA orphan drug status for IBD drug

Pharmaceutical Technology

PharmassêtX has received FDA orphan drug designation for epigallocatechin gallate (EGCG), to treat a rare form of IBD.

FDA 59
article thumbnail

Updated Guidelines for Statin Therapy in Patients With HIV

Pharmacy Times

Previous studies have shown that individuals living with HIV are at higher risk for heart disease than individuals without HIV

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers

Pharmaceutical Technology

Rgenta has secured approval for its IND application for RGT-61159, an oral small molecule RNA modulator, to treat cancers.

59
article thumbnail

Survey Finds Individuals With Dry Eye Are Unsure How to Prevent or Treat Their Symptoms

Pharmacy Times

Prevalence of dry eye is increasing drastically, especially in younger individuals, because of the current lifestyle and increased technology use.

55
article thumbnail

From Winnipeg to Brandon: Exploring Market Opportunities with Manitoba’s Top Doctors

Scott’s Directories

In Manitoba, the healthcare sector thrives, offering vast market opportunities. For businesses targeting this industry, access to a comprehensive physician directory in Manitoba is invaluable. Whether you’re a pharmaceutical company, a medical equipment supplier, or a healthcare recruiter, having a detailed Manitoba medical directory can significantly enhance your outreach efforts.

Doctors 52
article thumbnail

High-Dose Intravenous Immunoglobulin Responsive to Platelet-Activating Anti-PF4 Disorder

Pharmacy Times

Intravenous immunoglobulin was effective as an adjunctive treatment to anticoagulation in a patient with post-viral platelet-activating anti-PF4 disorder, indicating the need for accurate diagnosis and treatment selection.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A